Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in vivo Study
2020-001416-15Phase 2Completed
- Sponsor
- Knappschaft Kliniken Universitätsklinikum Bochum
- Start
- Jan 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceftazidime + avibactam in bacterial disease, sponsored by Knappschaft Kliniken Universitätsklinikum Bochum. Primary endpoint: CAZ/AVI concentrations in bile fluid. Started Jan 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2020-001416-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001416-15.